Arrowhead Research Corporation - ARWR STOCK NEWS

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported a fiscal Q1 2023 net loss of $41.3 million, or $0.39 per diluted share, a reduction from a net loss of $62.9 million in Q1 2022. Revenue increased to $62.5 million, compared to $27.4 million the previous year. The company achieved significant milestones, earning $40 million from Amgen and Horizon Therapeutics. A Phase 2 SEQUOIA study showed fibrosis regression in 50% of patients treated with investigational fazirsiran. The company's cash, cash equivalents, and investments totaled $617.6 million as of December 31, 2022, up from $482.3 million at September 30, 2022.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated a Phase 1/2a clinical trial for ARO-MMP7, targeting matrix metalloproteinase 7 (MMP7) to treat idiopathic pulmonary fibrosis (IPF). The trial, AROMMP7-1001, will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 56 healthy volunteers and 21 IPF patients. MMP7 is implicated in IPF's progression, causing inflammation and fibrosis. The trial’s results could address the significant unmet medical need for IPF patients, aiming to enhance lung function beyond current therapies. The ongoing research may position Arrowhead favorably in the competitive biotech landscape.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter, ending December 31, 2022. Investors can access the live audio webcast on the company's website, and a replay will be available shortly after. The call will cover the company's progress in developing medicines that target intractable diseases through RNA interference (RNAi), which silences genes responsible for these conditions.

Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced positive results from the Phase 2 SEQUOIA study for fazirsiran in treating liver disease due to alpha-1 antitrypsin deficiency (AATD-LD). Notable findings include a 50% fibrosis regression in patients and a 94% median reduction in liver Z-AAT accumulation. Adverse events were balanced between treatment and placebo groups. A Phase 3 study is set to begin this month, aiming to confirm these promising Phase 2 results.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET in San Francisco. This event is a significant platform for healthcare companies to discuss innovations and business strategies.

A webcast of the presentation will be accessible on the Arrowhead Pharmaceuticals website under the Investors section.

Arrowhead Pharmaceuticals (ARWR) announced it will present topline data from its SEQUOIA Phase 2 study of fazirsiran on January 9, 2023, at 8:30 a.m. ET. This investigational RNA interference therapy aims to treat alpha-1 antitrypsin deficiency, a rare genetic liver disease. The Phase 3 study will be co-developed with Takeda. AAT deficiency affects 1 in 3,000-5,000 individuals in the U.S. Arrowhead and Takeda's collaboration includes a profit-sharing structure and potential milestone payments exceeding $1 billion.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a $25 million milestone payment from Amgen (NASDAQ: AMGN) triggered by the enrollment of the first subject in Amgen's Phase 3 trial of olpasiran. Arrowhead is also in line to receive up to $535 million in additional milestone payments from Amgen and Royalty Pharma (NASDAQ: RPRX). The olpasiran therapy targets lipoprotein(a) to reduce cardiovascular disease risk. This milestone represents significant progress for Arrowhead, being the second TRiM-enabled candidate to enter Phase 3 trials, with more projected to follow in the coming year.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced on December 9, 2022 the approval of inducement grants for 35 new employees, totaling up to 84,000 restricted stock units. These grants, approved by the Compensation Committee, are issued outside of the company’s stockholder-approved equity incentive plans and will vest annually over four years. Arrowhead develops innovative therapies for intractable diseases through RNA interference, targeting the genes responsible for these conditions.

Horizon Therapeutics plc (Nasdaq: HZNP) announced the dosing of the first subject in a Phase 1 clinical trial for HZN-457, a small interfering RNA designed to treat gout by silencing liver xanthine dehydrogenase. This trial aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 56 healthy volunteers. Gout affects over 9 million patients in the U.S., with many inadequately treated by current therapies. HZN-457 aims to lower uric acid levels effectively, potentially improving patient outcomes. The development is part of a collaboration with Arrowhead Pharmaceuticals (Nasdaq: ARWR).